Millesimo M, Elia E, Marengo G, De Filippo O, Raposeiras-Roubin S, Wanha W, Abu-Assi E, Kinnaird T, Ariza-Sole A, Liebetrau C, Manzano-Fernandez S, Iannaccone M, Henriques JPS, Templin C, Wilton SB, Velicki L, Xanthopoulou I, Correia L, Cerrato E, Rognoni A, Nunez-Gil I, Song X, Kawaji T, Quadri G, Huczek Z, Paz RC, Juanatey JRG, Nie SP, Kawashiri MA, Dominguez-Rodriguez A, Conrotto F, D'Ascenzo F, De Ferrari GM. Antithrombotic Strategy in Secondary Prevention for High-Risk Patients with Previous Acute Coronary Syndrome: Overlap between the PEGASUS Eligibility and the COMPASS Eligibility in a Large Multicenter Registry. Am J Cardiovasc Drugs. 2023 Jan;23(1):77-87. doi: 10.1007/s40256-022-00554-5. Epub 2022 Oct 31. PubMed PMID: 36316613.
AÑO: 2023; IF: 2.8
